Skip to main content

Anaplastic Thyroid Carcinoma, Version 2.2015.

Publication ,  Journal Article
Haddad, RI; Lydiatt, WM; Ball, DW; Busaidy, NL; Byrd, D; Callender, G; Dickson, P; Duh, Q-Y; Ehya, H; Haymart, M; Hoh, C; Hunt, JP; Iagaru, A ...
Published in: J Natl Compr Canc Netw
September 2015

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosages and frequency of administration are now provided, docetaxel/doxorubicin regimens were added, and single-agent cisplatin was deleted because it is not recommended for patients with advanced or metastatic anaplastic thyroid cancer.

Duke Scholars

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

September 2015

Volume

13

Issue

9

Start / End Page

1140 / 1150

Location

United States

Related Subject Headings

  • Thyroidectomy
  • Thyroid Neoplasms
  • Thyroid Carcinoma, Anaplastic
  • Taxoids
  • Radiotherapy, Intensity-Modulated
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Humans
  • Doxorubicin
  • Docetaxel
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Haddad, R. I., Lydiatt, W. M., Ball, D. W., Busaidy, N. L., Byrd, D., Callender, G., … Hughes, M. (2015). Anaplastic Thyroid Carcinoma, Version 2.2015. J Natl Compr Canc Netw, 13(9), 1140–1150. https://doi.org/10.6004/jnccn.2015.0139
Haddad, Robert I., William M. Lydiatt, Douglas W. Ball, Naifa Lamki Busaidy, David Byrd, Glenda Callender, Paxton Dickson, et al. “Anaplastic Thyroid Carcinoma, Version 2.2015.J Natl Compr Canc Netw 13, no. 9 (September 2015): 1140–50. https://doi.org/10.6004/jnccn.2015.0139.
Haddad RI, Lydiatt WM, Ball DW, Busaidy NL, Byrd D, Callender G, et al. Anaplastic Thyroid Carcinoma, Version 2.2015. J Natl Compr Canc Netw. 2015 Sep;13(9):1140–50.
Haddad, Robert I., et al. “Anaplastic Thyroid Carcinoma, Version 2.2015.J Natl Compr Canc Netw, vol. 13, no. 9, Sept. 2015, pp. 1140–50. Pubmed, doi:10.6004/jnccn.2015.0139.
Haddad RI, Lydiatt WM, Ball DW, Busaidy NL, Byrd D, Callender G, Dickson P, Duh Q-Y, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McCaffrey JC, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Hoffmann KG, Hughes M. Anaplastic Thyroid Carcinoma, Version 2.2015. J Natl Compr Canc Netw. 2015 Sep;13(9):1140–1150.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

September 2015

Volume

13

Issue

9

Start / End Page

1140 / 1150

Location

United States

Related Subject Headings

  • Thyroidectomy
  • Thyroid Neoplasms
  • Thyroid Carcinoma, Anaplastic
  • Taxoids
  • Radiotherapy, Intensity-Modulated
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Humans
  • Doxorubicin
  • Docetaxel